Literature DB >> 9572089

The dexamethasone suppression test in schizophrenia.

K Ismail1, R M Murray, M J Wheeler, V O'Keane.   

Abstract

BACKGROUND: Cortisol non-suppression following the dexamethasone suppression test (DST) has been found to a variable extent in schizophrenia. The aetiology is unclear but may be related to depression or negative symptoms.
METHODS: The DST was administered to 64 patients with DSM-IV schizophrenia. All patients were screened for DSM-IV major depression and rated on the Hamilton Rating Scale for Depression (HRSD), Scale for Assessment of Negative Symptoms (SANS) and the Brief Psychiatric Rating Scale (BPRS).
RESULTS: DSM-IV criteria for major depression was fulfilled by 36% of the patients and 42% of patients had a history of parasuicide. Four patients had undetectable levels of dexamethasone and were excluded from the endocrine analyses. Only one remaining patient had a cortisol level above the cut-off point (> 138 nmol/l), indicating escape from dexamethasone suppression. The post-dexamethasone cortisol level correlated significantly with HRSD and BPRS scores but not with the SANS. The SANS and HRSD scores were not correlated, but they were independently correlated with the BPRS score.
CONCLUSIONS: In contrast to some other work, rates of dexamethasone non-suppression were very low; together with the high rates of depression, this suggests that depression in schizophrenia may have a different neuroendocrine profile from major depressive disorders. Failure to measure dexamethasone levels can be misleading.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9572089     DOI: 10.1017/s0033291797006521

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  6 in total

1.  A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism.

Authors:  H Y Chan; C J Chang; S C Chiang; J J Chen; C H Chen; H J Sun; H G Hwu; M S Lai
Journal:  J Psychopharmacol       Date:  2008-09-18       Impact factor: 4.153

Review 2.  Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.

Authors:  Peter M Haddad; Angelika Wieck
Journal:  Drugs       Date:  2004       Impact factor: 9.546

3.  Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: the role of stress and of antipsychotic treatment.

Authors:  Valeria Mondelli; Paola Dazzan; Nilay Hepgul; Marta Di Forti; Monica Aas; Alessandro D'Albenzio; Marco Di Nicola; Helen Fisher; Rowena Handley; Tiago Reis Marques; Craig Morgan; Serena Navari; Heather Taylor; Andrew Papadopoulos; Katherine J Aitchison; Robin M Murray; Carmine M Pariante
Journal:  Schizophr Res       Date:  2009-09-13       Impact factor: 4.939

4.  Possible association between interleukin-1β gene and schizophrenia in a Japanese population.

Authors:  Daimei Sasayama; Hiroaki Hori; Toshiya Teraishi; Kotaro Hattori; Miho Ota; Yoshimi Iijima; Masahiko Tatsumi; Teruhiko Higuchi; Naoji Amano; Hiroshi Kunugi
Journal:  Behav Brain Funct       Date:  2011-08-16       Impact factor: 3.759

5.  Mifepristone (RU-486) treatment for depression and psychosis: a review of the therapeutic implications.

Authors:  Peter Gallagher; Allan H Young
Journal:  Neuropsychiatr Dis Treat       Date:  2006-03       Impact factor: 2.570

Review 6.  A new nosology of psychosis and the pharmacological basis of affective and negative symptom dimensions in schizophrenia.

Authors:  Costa Vakalopoulos
Journal:  Ment Illn       Date:  2010-05-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.